VHB937 clinical trial overview

This Phase 2 study tests VHB937 in people with early-stage amyotrophic lateral sclerosis, within two years of symptom onset, in a 40-week double-blind period followed by an open-label extension. It asks how long people stay free of permanent ventilator support, how daily function changes using the revised functional rating scale, and what adverse events occur, aiming to show safety and potential slowing of decline for hope.